Show simple item record

dc.contributor.authorFinerty, S
dc.contributor.authorMackett, Mike
dc.contributor.authorArrand, John R
dc.contributor.authorWatkins, P E
dc.contributor.authorTarlton, J
dc.contributor.authorMorgan, A J
dc.date.accessioned2010-04-09T11:22:57Z
dc.date.available2010-04-09T11:22:57Z
dc.date.issued1994-10
dc.identifier.citationImmunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum. 1994, 12 (13):1180-4 Vaccineen
dc.identifier.issn0264-410X
dc.identifier.pmid7839721
dc.identifier.doi10.1016/0264-410X(94)90240-2
dc.identifier.urihttp://hdl.handle.net/10541/96126
dc.description.abstractThe Epstein-Barr virus (EBV) is associated with a range of life-threatening diseases in humans. Development of an effective vaccine has therefore been an important objective. One problem in the development of a subunit vaccine for human administration is the selection of a satisfactory adjuvant since the only one currently licensed for human use is alum, although this is not considered to be very effective. The present study demonstrated that a subunit vaccine composed of the EBV envelope glycoprotein gp340 with alum as the adjuvant did elicit protective immunity against EBV-induced lymphoma in three out of five cottontop tamarins. Furthermore, rabbits immunized with gp340/alum developed the same range of antibody responses as rabbits immunized with gp340/SAF-1, an experimental adjuvant claimed to be more effective than alum. Therefore, these results indicate that alum should be evaluated as an adjuvant as part of a human trial of a gp340-based subunit vaccine.
dc.language.isoenen
dc.subject.meshAdjuvants, Immunologic
dc.subject.meshAlum Compounds
dc.subject.meshAnimals
dc.subject.meshAntibodies, Viral
dc.subject.meshAntigens, Viral
dc.subject.meshFemale
dc.subject.meshHerpesviridae Infections
dc.subject.meshHerpesvirus 4, Human
dc.subject.meshHumans
dc.subject.meshImmunization
dc.subject.meshMale
dc.subject.meshRabbits
dc.subject.meshSaguinus
dc.subject.meshTumor Virus Infections
dc.subject.meshVaccines, Synthetic
dc.subject.meshViral Matrix Proteins
dc.subject.meshViral Vaccines
dc.titleImmunization of cottontop tamarins and rabbits with a candidate vaccine against the Epstein-Barr virus based on the major viral envelope glycoprotein gp340 and alum.en
dc.typeArticleen
dc.contributor.departmentDepartment of Pathology, School of Medical Sciences, University of Bristol, UK.en
dc.identifier.journalVaccineen
html.description.abstractThe Epstein-Barr virus (EBV) is associated with a range of life-threatening diseases in humans. Development of an effective vaccine has therefore been an important objective. One problem in the development of a subunit vaccine for human administration is the selection of a satisfactory adjuvant since the only one currently licensed for human use is alum, although this is not considered to be very effective. The present study demonstrated that a subunit vaccine composed of the EBV envelope glycoprotein gp340 with alum as the adjuvant did elicit protective immunity against EBV-induced lymphoma in three out of five cottontop tamarins. Furthermore, rabbits immunized with gp340/alum developed the same range of antibody responses as rabbits immunized with gp340/SAF-1, an experimental adjuvant claimed to be more effective than alum. Therefore, these results indicate that alum should be evaluated as an adjuvant as part of a human trial of a gp340-based subunit vaccine.


Files in this item

This item appears in the following Collection(s)

Show simple item record